Is Gilead Sciences (GILD) a risky stock?
As of July 21, 2026, Clavix grades Gilead Sciences (GILD) B+ for risk, a composite score of 74 out of 100 on an A+ to F scale, which puts GILD in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind GILD's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how GILD scores on each, as of July 21, 2026.
What's moving GILD's risk right now
Company-specific signals Clavix flags behind GILD's current grade, drawn from recent news and filings as of July 21, 2026.
Biktarvy, Gilead's top-selling HIV treatment, could see sales erode as generic and biosimilar versions enter the market once its patent expires. That competition may weigh on Gilead's long-term revenue and earnings.
Gilead is partnering with Cognizant to modernize IT service delivery using ServiceNow and AI-enabled tools, aiming for faster support and less day-to-day friction for staff. It's an internal operational upgrade, not a direct sales catalyst.
What a B+ grade means
On the Clavix A+ to F scale, GILD's composite of 74 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell GILD or any security. Grades are risk indicators, not predictions of return. Data may be delayed.